<DOC>
	<DOCNO>NCT02282527</DOCNO>
	<brief_summary>Grifols Therapeutics Inc. conduct multi-center , randomize , double-blind , crossover study evaluate safety , immunogenicity , pharmacokinetics ( PK ) Liquid Alpha₁-PI compare currently license product , Prolastin-C , subject Alpha₁-Antitrypsin Deficiency ( AATD ) .</brief_summary>
	<brief_title>A Study Assess Safety PK Liquid Alpha₁-Proteinase Inhibitor ( Human ) Treating Alpha₁-Antitrypsin Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Be 18 70 year age , inclusive Had diagnosis congenital AATD Had document total alpha₁PI level &lt; 11 µM . If total alpha₁PI level yet document , blood draw total alpha₁PI level obtain Screening Visit Had postbronchodilator Forced expiratory volume 1 second ( FEV1 ) ≥ 30 % &lt; 80 % predict FEV1/forced vital capacity ( FVC ) &lt; 70 % If subject receive alpha₁PI augmentation therapy kind , he/she must willing discontinue treatment Week 1 ( Baseline ) Visit remain kind alpha₁PI treatment , investigational product study , participate study Subject moderate severe pulmonary exacerbation 4 week Week 1 ( Baseline ) Visit History lung liver transplant Any lung surgery past 2 year ( exclude lung biopsy ) Liver cirrhosis confirm biopsy Elevated liver enzyme ( aspartate transaminase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase [ ALP ] ) equal great 2.5 time upper limit normal Severe concomitant disease ( e.g. , congestive heart failure , clinically significant pulmonary fibrosis , malignant disease [ exception skin cancer melanoma ] , history acute hypersensitivity pneumonitis reaction , current chronic hypersensitivity pneumonitis ) Females pregnant , breastfeeding , childbearing potential , unwilling practice highly effective method contraception ( oral , injectable implanted hormonal method contraception , placement intrauterine device ( IUD ) intrauterine system ( IUS ) , condom occlusive cap spermicidal foam/gel/film/cream/suppository , male sterilization , abstinence ) throughout study Known previous infection clinical sign symptoms consistent current hepatitis A virus ( HAV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) infection Smoking past 6 month positive urine cotinine test Screening Visit due smoke Participation another investigational drug study within one month prior Week 1 ( Baseline ) Visit History anaphylaxis severe systemic response plasmaderived alpha1PI preparation blood product ( ) Use systemic steroid stable dose equivalent 5 mg/day prednisone ( i.e.,10 mg every 2 day ) within 4 week prior Week 1 ( Baseline ) Visit inhale steroid consider systemic steroid ) Use systemic aerosolized antibiotic exacerbation within 4 week prior Week 1 ( Baseline ) Visit Known selective severe Immunoglobulin A ( IgA ) deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>